2023
Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease
Ackley W, Dahl N, Park M. Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease. Advances In Kidney Disease And Health 2023, 30: 228-235. PMID: 37088525, DOI: 10.1053/j.akdh.2023.02.002.Peer-Reviewed Original ResearchConceptsAutosomal dominant polycystic kidney diseaseEnd-stage kidney diseaseKidney diseaseDominant polycystic kidney diseasePolycystic kidney diseaseRapid progressionMechanism-specific treatmentsChronic kidney diseaseFourth leading causeTreatment of patientsPharmacologic managementLeading causeKidney disordersFDA approvalDiseaseTolvaptanProgressionTreatmentRiskMorbidityPatientsPathogenesisTherapy
2019
Nephrolithiasis in the Elderly
Dahl N, Goldfarb D. Nephrolithiasis in the Elderly. 2019, 201-212. DOI: 10.1007/978-3-030-18711-8_14.Peer-Reviewed Original Research
2011
Should Living Kidney Donor Candidates with Impaired Fasting Glucose Donate?
Vigneault CB, Asch WS, Dahl NK, Bia MJ. Should Living Kidney Donor Candidates with Impaired Fasting Glucose Donate? Clinical Journal Of The American Society Of Nephrology 2011, 6: 2054-2059. PMID: 21784837, DOI: 10.2215/cjn.03370411.BooksConceptsTransplant centersLiving donorsDonor candidatesGreater riskImpaired glucose toleranceImpaired glucose metabolismDefinition of diabetesPotential living donorsKidney donor candidatesFuture diabetesKidney transplantMetabolic syndromeGlucose toleranceKidney donorsDonor screeningTransplant guidelinesHispanic ethnicityGlucose metabolismDiabetesHispanic individualsPotential donorsIFGRiskDonorsEthnicity